CompletedN/Aketamine

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

Sponsored by Psych Atlanta

NCT ID
NCT04856124
Target Enrollment
10 participants
Start Date
2018-09-01
Est. Completion
2021-03-01

About This Study

This study aims to assess the efficacy and safety of intranasal esketamine as maintenance antidepressant therapy in patients who have demonstrated clinical improvement with off-label intravenous racemic ketamine for treatment-resistant depression.

Conditions Studied

Treatment Resistant Depression

Interventions

  • •Intranasal esketamine

Eligibility

Age:18 Years - N/A
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria:

Diagnosis of major depression, recurrent, severe without psychotic symptoms according to criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Must be diagnosed with Treatment resistant depression.

18 years old and up Patients had a clinically meaningful response to a course of IV racemic ketamine

Exclusion Criteria:

Active substance abuse, psychosis, significant medical comorbidities, or axis II diagnosis that would interfere with the reliability of outcome measures or response to pharmacotherapy.

Study Locations (1)

PsychAtlanta
Marietta, Georgia, United States

This trial is not recruiting

This study has completed enrollment. Check back for results or find similar trials.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine | Huxley